{"success":true,"data":{"pressRelease":{"id":"168832","rtpr_id":"nGNX7jty42-20261014","ticker":"ADAG","exchange":"NASDAQ","all_tickers":["ADAG","978Y"],"title":"Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference","author":"Globe Newswire","published_at":"2026-10-14T12:00:02.366Z","article_body":"SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc.\n(Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company\ntransforming the discovery and development of novel antibody-based therapies,\ntoday announced that Adagene’s Chief Executive Officer and President of R&D,\nPeter Luo, Ph.D., will participate in a fireside chat at the H.C. Wainwright\n4(th) Annual Immune Cell Engager Virtual Conference being held virtually on\nOctober 15, 2026.\n\nH.C. Wainwright 4(th) Annual Immune Cell Engager Virtual Conference\nFormat: Fireside chat\nDate: October 15, 2026\nTime: 1:30 – 2:00 p.m. ET\n\nA webcast of the fireside chat will be accessible in the Investors\n(https://www.globenewswire.com/Tracker?data=WmHJ-NejUwL5i0bunbgvg7pLNgV7KSPa12ecjnAKMvm4s1K2tH0aUKaE_pFp4swp31JbVjYsnOnXlBaUcIktiXg60xWIB_PatuJO4l-jnTY=) section\nof the Company’s website at https://www.adagene.com for at least 30 days\nfollowing the conference.\n\nAbout Adagene\n\nAdagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology\ncompany committed to transforming the discovery and development of novel\nantibody-based cancer immunotherapies. Adagene combines computational biology\nand artificial intelligence to design novel antibodies that address globally\nunmet patient needs. The company has forged strategic collaborations with\nreputable global partners that leverage its SAFEbody® precision masking\ntechnology in multiple approaches at the vanguard of science.\n\nPowered by its proprietary Dynamic Precision Library (DPL) platform, composed\nof NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly\ndifferentiated pipeline features novel immunotherapy programs. The company’s\nSAFEbody technology is designed to address safety and tolerability challenges\nassociated with many antibody therapeutics by using precision masking\ntechnology to shield the binding domain of the biologic therapy. Through\nactivation in the tumor microenvironment, this allows for tumor-specific\ntargeting of antibodies, while minimizing on-target off-tumor toxicity in\nhealthy tissues.\n\nAdagene’s lead clinical program, muzastotug (ADG126), is a masked,\nanti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique\nepitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment.\nMuzastotug is currently in Phase 1b/2 and Phase 2 clinical studies in\ncombination with anti-PD-1 therapy, particularly focused on microsatellite\nstable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical\nresearch, the SAFEbody platform can be applied to a wide variety of\nantibody-based therapeutic modalities, including Fc empowered antibodies,\nantibody-drug conjugates, and bi/multi-specific T-cell engagers.\n\nFor more information, please visit: https://investor.adagene.com/\nFollow Adagene on WeChat\n(https://www.globenewswire.com/Tracker?data=lmCQ1YdFatZ0roBAx9suR_dXmyqBMhonkl-At3tnlqvxTVnB0xuyAGbZD38zFdzPAnWY51a61ZOKcp26e7jddS4Vh4povdAwMpFKs8MrkARwgKCOcoW2w2irWgIdVR6V1bCTOPQG_lF1Tb3LQ0BDU93o1CMPmZa2lhwgBH1w9YO7inBBIJVsA8Mc5Rfc9nqw),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=B3kR1zy9wQq-gOULrWnIqwmZG9IhXIWg-is8w7MstIQm1fAar4O5tuG2b71HUn9Fd-pnbKMMVAooZbcj7A26pzj4Qjp9rbpqeeIZA6dzD8m5YWde6O3JCu1uQ3Nn_HP0)\nand X\n(https://www.globenewswire.com/Tracker?data=4opb54T4U-u2_m_SMTboHDdGffwpsuvGfnXWu9stRaTOC8_i2fSkSHKrDxJ1c4GPgNBvqmaLMwfJeIUoVrdO5Q==).\n\nSAFEbody(®) is a registered trademark in the United States, China, Australia,\nJapan, Singapore, and the European Union.\n\nSafe Harbor Statement\nThis press release contains forward-looking statements, including statements\nregarding the potential implications of clinical data for patients and\nAdagene’s advancement of, and anticipated preclinical activities, clinical\ndevelopment, regulatory milestones, and commercialization of its product\ncandidates. Actual results may differ materially from those indicated in the\nforward-looking statements as a result of various important factors, including\nbut not limited to Adagene’s ability to demonstrate the safety and efficacy\nof its drug candidates; the clinical results for its drug candidates, which\nmay not support further development or regulatory approval; the content and\ntiming of decisions made by the relevant regulatory authorities regarding\nregulatory approval of Adagene’s drug candidates; Adagene’s ability to\nachieve commercial success for its drug candidates, if approved; Adagene’s\nability to obtain and maintain protection of intellectual property for its\ntechnology and drugs; Adagene’s reliance on third parties to conduct drug\ndevelopment, manufacturing and other services; Adagene’s limited operating\nhistory and Adagene’s ability to obtain additional funding for operations\nand to complete the development and commercialization of its drug candidates;\nAdagene’s ability to enter into additional collaboration agreements beyond\nits existing strategic partnerships or collaborations, and the impact of the\nCOVID-19 pandemic on Adagene’s clinical development, commercial and other\noperations, as well as those risks more fully discussed in the “Risk\nFactors” section in Adagene’s filings with the U.S. Securities and\nExchange Commission. All forward-looking statements are based on information\ncurrently available to Adagene, and Adagene undertakes no obligation to\npublicly update or revise any forward-looking statements, whether as a result\nof new information, future events or otherwise, except as may be required by\nlaw.\n\nInvestor Contacts:\nRaymond Tam\nRaymond_tam@adagene.com\n\nCorey Davis\nLifeSci Advisors\ncdavis@lifesciadvisors.com\n\nMedia Contact:\nMichael Fitzhugh\nLifeSci Communications\nmfitzhugh@lifescicomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c377318b-edf7-42c0-8e7c-63a02bbe47b0)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7jty42-20261014","title":"Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference","author":"Globe Newswire","ticker":"ADAG","created":"2026-10-14T12:00:02.366Z","tickers":["ADAG","978Y"],"exchange":"NASDAQ","article_body":"SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc.\n(Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company\ntransforming the discovery and development of novel antibody-based therapies,\ntoday announced that Adagene’s Chief Executive Officer and President of R&D,\nPeter Luo, Ph.D., will participate in a fireside chat at the H.C. Wainwright\n4(th) Annual Immune Cell Engager Virtual Conference being held virtually on\nOctober 15, 2026.\n\nH.C. Wainwright 4(th) Annual Immune Cell Engager Virtual Conference\nFormat: Fireside chat\nDate: October 15, 2026\nTime: 1:30 – 2:00 p.m. ET\n\nA webcast of the fireside chat will be accessible in the Investors\n(https://www.globenewswire.com/Tracker?data=WmHJ-NejUwL5i0bunbgvg7pLNgV7KSPa12ecjnAKMvm4s1K2tH0aUKaE_pFp4swp31JbVjYsnOnXlBaUcIktiXg60xWIB_PatuJO4l-jnTY=) section\nof the Company’s website at https://www.adagene.com for at least 30 days\nfollowing the conference.\n\nAbout Adagene\n\nAdagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology\ncompany committed to transforming the discovery and development of novel\nantibody-based cancer immunotherapies. Adagene combines computational biology\nand artificial intelligence to design novel antibodies that address globally\nunmet patient needs. The company has forged strategic collaborations with\nreputable global partners that leverage its SAFEbody® precision masking\ntechnology in multiple approaches at the vanguard of science.\n\nPowered by its proprietary Dynamic Precision Library (DPL) platform, composed\nof NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly\ndifferentiated pipeline features novel immunotherapy programs. The company’s\nSAFEbody technology is designed to address safety and tolerability challenges\nassociated with many antibody therapeutics by using precision masking\ntechnology to shield the binding domain of the biologic therapy. Through\nactivation in the tumor microenvironment, this allows for tumor-specific\ntargeting of antibodies, while minimizing on-target off-tumor toxicity in\nhealthy tissues.\n\nAdagene’s lead clinical program, muzastotug (ADG126), is a masked,\nanti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique\nepitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment.\nMuzastotug is currently in Phase 1b/2 and Phase 2 clinical studies in\ncombination with anti-PD-1 therapy, particularly focused on microsatellite\nstable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical\nresearch, the SAFEbody platform can be applied to a wide variety of\nantibody-based therapeutic modalities, including Fc empowered antibodies,\nantibody-drug conjugates, and bi/multi-specific T-cell engagers.\n\nFor more information, please visit: https://investor.adagene.com/\nFollow Adagene on WeChat\n(https://www.globenewswire.com/Tracker?data=lmCQ1YdFatZ0roBAx9suR_dXmyqBMhonkl-At3tnlqvxTVnB0xuyAGbZD38zFdzPAnWY51a61ZOKcp26e7jddS4Vh4povdAwMpFKs8MrkARwgKCOcoW2w2irWgIdVR6V1bCTOPQG_lF1Tb3LQ0BDU93o1CMPmZa2lhwgBH1w9YO7inBBIJVsA8Mc5Rfc9nqw),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=B3kR1zy9wQq-gOULrWnIqwmZG9IhXIWg-is8w7MstIQm1fAar4O5tuG2b71HUn9Fd-pnbKMMVAooZbcj7A26pzj4Qjp9rbpqeeIZA6dzD8m5YWde6O3JCu1uQ3Nn_HP0)\nand X\n(https://www.globenewswire.com/Tracker?data=4opb54T4U-u2_m_SMTboHDdGffwpsuvGfnXWu9stRaTOC8_i2fSkSHKrDxJ1c4GPgNBvqmaLMwfJeIUoVrdO5Q==).\n\nSAFEbody(®) is a registered trademark in the United States, China, Australia,\nJapan, Singapore, and the European Union.\n\nSafe Harbor Statement\nThis press release contains forward-looking statements, including statements\nregarding the potential implications of clinical data for patients and\nAdagene’s advancement of, and anticipated preclinical activities, clinical\ndevelopment, regulatory milestones, and commercialization of its product\ncandidates. Actual results may differ materially from those indicated in the\nforward-looking statements as a result of various important factors, including\nbut not limited to Adagene’s ability to demonstrate the safety and efficacy\nof its drug candidates; the clinical results for its drug candidates, which\nmay not support further development or regulatory approval; the content and\ntiming of decisions made by the relevant regulatory authorities regarding\nregulatory approval of Adagene’s drug candidates; Adagene’s ability to\nachieve commercial success for its drug candidates, if approved; Adagene’s\nability to obtain and maintain protection of intellectual property for its\ntechnology and drugs; Adagene’s reliance on third parties to conduct drug\ndevelopment, manufacturing and other services; Adagene’s limited operating\nhistory and Adagene’s ability to obtain additional funding for operations\nand to complete the development and commercialization of its drug candidates;\nAdagene’s ability to enter into additional collaboration agreements beyond\nits existing strategic partnerships or collaborations, and the impact of the\nCOVID-19 pandemic on Adagene’s clinical development, commercial and other\noperations, as well as those risks more fully discussed in the “Risk\nFactors” section in Adagene’s filings with the U.S. Securities and\nExchange Commission. All forward-looking statements are based on information\ncurrently available to Adagene, and Adagene undertakes no obligation to\npublicly update or revise any forward-looking statements, whether as a result\nof new information, future events or otherwise, except as may be required by\nlaw.\n\nInvestor Contacts:\nRaymond Tam\nRaymond_tam@adagene.com\n\nCorey Davis\nLifeSci Advisors\ncdavis@lifesciadvisors.com\n\nMedia Contact:\nMichael Fitzhugh\nLifeSci Communications\nmfitzhugh@lifescicomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c377318b-edf7-42c0-8e7c-63a02bbe47b0)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-14T12:00:03.069756073Z","server_sent_at_ms":1791979203069},"received_at":"2026-10-14T12:00:03.121Z","source_url":null},"analysis":{"id":"157088","press_release_id":"168832","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Adagene announced that CEO Peter Luo will participate in a fireside chat at the H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference on October 15, 2026, from 1:30 to 2:00 p.m. ET.\n\nA webcast will be available on the company's investor website for at least 30 days after the conference.\n\nThe release contains no new clinical or financial data; it is a routine investor-relations scheduling notice, though it repeats that lead program muzastotug (ADG126) holds FDA Fast Track designation and is in Phase 1b/2 and Phase 2 studies in MSS metastatic colorectal cancer.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference participation notice -- no actionable content; suppress or archive for IR calendar."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Peter Luo, Ph.D.","role":"CEO and President of R&D"},{"name":"Raymond Tam","role":"Investor contact"},{"name":"Corey Davis","role":"LifeSci Advisors investor contact"},{"name":"Michael Fitzhugh","role":"LifeSci Communications media contact"}],"products":["muzastotug (ADG126)","SAFEbody","Dynamic Precision Library (DPL)","NEObody","POWERbody"],"companies":[{"name":"Adagene Inc.","ticker":"ADAG"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"LifeSci Advisors","relationship":"IR firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-relations announcement of a fireside chat at a virtual conference. No new data, guidance, or corporate action disclosed."},"tickerRelevance":{"others":[],"primary":"ADAG"},"globalImportance":8,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-participation-notice","issuerAuthored":true,"newInformation":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Adagene announced that CEO Peter Luo will participate in a fireside chat at the H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference on October 15, 2026, from 1:30 to 2:00 p.m. ET.\n\nA webcast will be available on the company's investor website for at least 30 days after the conference.\n\nThe release contains no new clinical or financial data; it is a routine investor-relations scheduling notice, though it repeats that lead program muzastotug (ADG126) holds FDA Fast Track designation and is in Phase 1b/2 and Phase 2 studies in MSS metastatic colorectal cancer.","key_figures":{},"named_entities":{"people":[{"name":"Peter Luo, Ph.D.","role":"CEO and President of R&D"},{"name":"Raymond Tam","role":"Investor contact"},{"name":"Corey Davis","role":"LifeSci Advisors investor contact"},{"name":"Michael Fitzhugh","role":"LifeSci Communications media contact"}],"products":["muzastotug (ADG126)","SAFEbody","Dynamic Precision Library (DPL)","NEObody","POWERbody"],"companies":[{"name":"Adagene Inc.","ticker":"ADAG"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"LifeSci Advisors","relationship":"IR firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T12:00:26.607Z","global_importance":8,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-participation-notice","issuerAuthored":true,"newInformation":false}},"durationMs":4658,"modelName":"glm-5.3-flashx"}}